United Therapeutics Corporation UTHR NASDAQ

United Therapeutics Corporation (UTHR) has shown strong revenue growth over the past 3 years, expanding from $1.9B to $3.2B (average +18.1%/yr). Net income reached $1.3B, reflecting exceptional earnings expansion at +22.8%/yr on average. The net profit margin is 41.9%, which is exceptional. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 87.9% (high), with a -4.5pp trend over the period. With a $25B market cap and MOAT composite score of 71/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 28-year history, the company was profitable in 20 of 28 years — a solid long-term record with occasional losses
• INCOME (100/100, Pass) — proves strong profitability and pricing power
• MOAT (71/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.